Personalis Inc

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Personalis Inc reports Q2 revenue growth, eyes strong collaborations

Personalis Inc is strategically positioned for growth in oncology with NeXT Personal and key collaborations, despite facing financial challenges and revenue fluctuations.
The company's strong balance sheet and prudent expense management offer financial stability and a 2-year cash runway, supporting future growth opportunities.
Legal battles and variability in data publication speed present challenges, but active engagement in scientific advancement and partnerships drive credibility and revenue potential.
Overall, Personalis is navigating a complex landscape with a focus on innovation, financial sustainability, and scientific credibility to drive future success.

Personalis Inc reports strong Q3 growth and strategic partnerships

Personalis Inc's Q3 performance reflects growth in key revenue segments and strategic advancements in cancer research collaborations and product launches.
While facing challenges in net losses and reimbursement coverage, the company's focus on partnerships, operational efficiency, and revenue growth presents opportunities for market expansion.
With a strong cash position, reduced OpEx, and plans for revenue growth, Personalis Inc is poised for strategic growth and market capture in the genomics industry.

Personalis Inc (PSNL) reports robust Q4 performance and strategic growth plans

Personalis Inc (PSNL) delivered strong financial performance in Q4 2023, with revenue growth, improved margins, and cost efficiency measures.
The company's focus on strategic collaborations, strong financial position, and targeted market approach position it well for future growth.
Challenges in revenue guidance, regulatory hurdles, and managing partnerships require careful navigation, but opportunities in key cancer areas offer significant growth potential.

Personalis Inc surpasses revenue targets, eyes MRD test leadership

Personalis Inc demonstrated strong financial performance in Q1 2024, exceeding revenue guidance.
The company's focus on MRD testing and strong IP protections positions it well for future growth.
Challenges lie in balancing test adoption with reimbursement considerations for sustained growth.
Opportunities exist to solidify NeXT Personal's position in clinical diagnostics through strategic planning.

Personalis Inc reports robust Q2 earnings, eyes growth opportunities

Personalis Inc delivered strong financial performance in Q2 2024, driven by revenue growth and strategic initiatives.
The company's focus on MRD testing, partnerships, and innovative strategies position them for future growth.
While challenges like market competition and cash management exist, opportunities in diversification and partnerships are promising.

Personalis Inc reports robust Q3 revenue growth and strategic expansion

Personalis Inc's Q3 performance reflects strong revenue growth and financial stability, underpinned by a focus on innovation and market expansion.
While facing challenges in achieving reimbursement and managing expenses, the company's strategic initiatives position it well for future growth and profitability.
With a clear roadmap for revenue expansion and a commitment to financial efficiency, Personalis Inc is poised to capitalize on growth opportunities in the MRD testing market.

Personalis Inc reports 15% revenue growth in 2024, eyes Medicare reimbursement

Personalis Inc showed strong revenue growth in 2024 but faced challenges in Q4 with lower volume and a net loss. The company's focus on MRD intellectual property and partnerships like Moderna position it well for future growth. Guidance for 2025 emphasizes volume growth and reimbursement achievements to drive revenue. With a solid balance sheet and strategic initiatives, Personalis is poised for continued success and innovation.

Personalis Inc excels in Q1, eyes MRD market growth

Personalis Inc's Q1 2025 showcased strong financial performance and strategic advancements in key markets. The company's focus on MRD testing and partnerships with biopharma customers position it for sustained growth. Challenges lie in competitive pressures, reimbursement hurdles, and maintaining operational efficiency. Opportunities include expanding clinical evidence, driving market adoption, and advancing technology capabilities.

Personalis Inc reports Q2 revenue decline, focuses on MRD growth

Personalis Inc faced revenue challenges in Q2 2025, driven by volume declines and delays in customer projects, leading to a net loss increase YoY. Despite financial pressures, the company is strategically focusing on MRD technology growth, Medicare reimbursement, and clinical adoption of key tests. Partnerships with Tempus and a commitment to excel in MRD present opportunities for commercialization and transformative impact on cancer care. To overcome challenges, Personalis needs to accelerate revenue growth, efficiently manage projects, and secure timely Medicare reimbursements for sustained success.

Personalis Inc. reports strong Q3 growth amidst margin challenges

Personalis Inc. demonstrated robust growth in clinical tests and revenue in Q3 2025, despite facing margin and expense challenges. The company's focus on innovative testing capabilities, reimbursement expansion, and strategic partnerships positions it well for future success. With a strong cash position and ongoing research initiatives, Personalis is poised to capitalize on market opportunities and drive long-term growth.

Personalis Inc reports strong Q4 earnings, eyes growth through innovation

Personalis Inc's Q4 2025 performance reflects robust revenue growth and strategic shifts towards higher-value partnerships, setting the stage for continued success. The company's focus on Clinical revenue expansion, innovative product enhancements, and market share gains position them well for future growth. While facing challenges in a competitive landscape, Personalis Inc's confidence in strategy execution and market positioning bodes well for sustained performance. Strategic investments in automation, evidence generation, and market expansion present promising opportunities for revenue growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.